Extracorporeal Photopheresis ( ECP ) for Refractory Lichenoid Disorders: A Retrospective Analysis of Efficacy and Long‐Term Outcomes
Journal of Clinical Apheresis · 2026-06 · 41 (3)
DOI: 10.1002/jca.70136 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Apheresis, online erschienen am 16.06.2026. Verfasst von Etienne Paubelle und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cell Therapy Laboratory, Amiens University Hospital, Amiens, France. Hauptthemen laut MEDLINE: Photopheresis, Lichen Planus, Lichenoid Eruptions. Die Arbeit nennt 12 Literaturangaben.
Abstract (Originalsprache)
Erosive Lichen Planus (ELP) is a debilitating T‐cell mediated dermatosis often refractory to conventional therapies. While Extracorporeal Photopheresis (ECP) is established for other T‐cell diseases, long‐term data on its efficacy across the lichenoid spectrum, including non‐erosive forms, remain limited. We conducted a retrospective study at Amiens‐Picardie University Hospital including five adult patients with refractory lichen (erosive or non‐erosive) treated with ECP after January 2021. Clinical response was assessed every 3 months, and progression‐free survival (PFS) was analyzed. Five female patients were included: 3 with ELP and 2 with lichen sclerosus (LS) variants. All patients achieved an initial clinical response (1 complete, 4 partial). The median time to best response was 7.5 months (95% CI: 0.8–13). At 3 months, 40% were on ECP monotherapy. Over a median follow‐up of 47 months, only one patient progressed. At the last follow‐up, two patients remained on ECP with sustained clinical benefit. Our results confirm the excellent long‐term efficacy and safety of ECP in refractory ELP. While significant initial benefits were observed in non‐erosive scleroatrophic lichen, the durability of response warrants further investigation. ECP is an effective, well‐tolerated, and sustained therapeutic option for refractory ELP and holds promise for non‐erosive lichenoid pathologies. Larger prospective studies are needed to clarify its role as monotherapy versus combination therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cell Therapy Laboratory, Amiens University Hospital, Amiens, France.
- Apheresis Unit, Amiens University Hospital, Amiens, France.
- HEMATIM-Haematopoiesis and Immunology (UR UPJV 4666), Amiens, France.
- Dermatology Department, Amiens University Hospital, Amiens, France.
Zitieren
APA
Paubelle, E., Merlusca, L., Petit, S., Theophile, L., Ghamlouch, H., Ossart, C., Bacquet, S., Marolleau, J. P., & Arnault, J. P. (2026). Extracorporeal Photopheresis ( ECP ) for Refractory Lichenoid Disorders: A Retrospective Analysis of Efficacy and Long‐Term Outcomes. Journal of Clinical Apheresis, 41(3). https://doi.org/10.1002/jca.70136
Vancouver
Paubelle E, Merlusca L, Petit S, Theophile L, Ghamlouch H, Ossart C, et al. Extracorporeal Photopheresis ( ECP ) for Refractory Lichenoid Disorders: A Retrospective Analysis of Efficacy and Long‐Term Outcomes. Journal of Clinical Apheresis. 2026;41(3). doi:10.1002/jca.70136
BibTeX
@article{Paubelle2026,
author = {Paubelle, Etienne and Merlusca, Lavinia and Petit, Sylvie and Theophile, Laetitia and Ghamlouch, Hussein and Ossart, Christel and Bacquet, Solenn and Marolleau, Jean-Pierre and Arnault, Jean-Philippe},
title = {Extracorporeal Photopheresis ( ECP ) for Refractory Lichenoid Disorders: A Retrospective Analysis of Efficacy and Long‐Term Outcomes},
journal = {Journal of Clinical Apheresis},
year = {2026},
volume = {41},
number = {3},
doi = {10.1002/jca.70136}
}
EUVIMED